Pharma channel feed – Endpoints News

Pharma channel feed

Kymriah wins second FDA OK, boosting hope for Novartis' low CAR-T sales

8 years ago

Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics

8 years ago

Biogen tosses in an extra $50M for a bigger slice of the royalties for its PhIII Alzheimer’s drug aducanumab

8 years ago

Sanofi/Regeneron’s one-two punch on PCSK9 price and health data wins a key convert as Express Scripts creates exclusive formulary deal

8 years ago

Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology

8 years ago

Spark's PRV draws lukewarm price, selling for $110M to Jazz

8 years ago

Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint

8 years ago

Ahead of Hong Kong listing changes, WuXi preps for a biotech boom with a new R&D center in Shanghai

8 years ago

Two more top FDA officials hit the exits as an exodus of senior regulators continues

8 years ago

Vertex's rapid-fire PhIII program hits a roadblock at the FDA. Will regulators force rival Galapagos to slow down too?

8 years ago

Acadia shares slide — again — after FDA confirms it has launched a safety review of Nuplazid

8 years ago

Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff

8 years ago

'Site-less' trials in mind, Novartis launches an app for ophthalmology research

8 years ago

Can Takeda actually close its $65B deal to buy Shire? Maybe, but analysts aren't sure they should

8 years ago

SCOTUS to biopharma: Inter partes reviews are here to stay, deal with it

8 years ago

FDA panel offers a wavering thumbs up for Eli Lilly's 2 mg baricitinib, thumbs down on 4 mg

8 years ago

EMA committee recommends Alnylam's early-stage ATTR amyloidosis drug for orphan status

8 years ago

Pfizer hits stumbling block on Herceptin rival, but wins 'breakthrough' status on MenB vaccine

8 years ago

Sage files for an approval for its ‘breakthrough’ therapy for postpartum depression

8 years ago

Penny stock biotech Synthetic Biologics sees its 'breakthrough' status pulled as FDA ponders safety issues

8 years ago

Dicerna shares rocket up on a $15M-plus-stock deal to settle Alnylam claims — will deals follow?

8 years ago

Arcturus takes another legal stab at former CEO as public battle turns serious for the company

8 years ago

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies

8 years ago

CHMP scolds AB Science (again) for masitinib shortcomings, triggering a new rout on stock price

8 years ago

First page Previous page 302 303 304305306 307 308 Next page Last page